Pulmonary Complication Induced by Imatinib: A Case Report of Nonspecific Interstitial Pneumonia

Abstract excerpt

<title>Abstract</title> <p>Background Chronic myeloid leukemia (CML) is a neoplasm marked by BCR-ABL gene fusion, leading to abnormal cell growth. Imatinib, a selective tyrosine kinase inhibitor, is first-line treatment for Philadelphia chromosome-positive CML. Side effects include hematologic toxicity and, rarely, pulmonary adverse events like interstitial pneumonitis, as seen in a unique 53-year-old patient ca...

Topics

Open a Topic to create a Post that cites this publication.

• Biomarkers
• Carcinoma, Non-Small-Cell Lung
• COVID-19
• ErbB Receptors
• Lung Diseases, Interstitial
• Mutation
• Phenotype
• SARS-CoV-2

Identifiers and source

Literature Corpus work

1916409c-ea61-5f6c-99ce-d2ba982c09e8

DOI

10.21203/rs.3.rs-6745734/v1